Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Kobe, Carsten  [Clear All Filters]
2024
Rosenbrock J, Kaul H, Oertel M, Celik E, Linde P, Fan J, Eichenauer DA, Broeckelmann PJ, von Tresckow B, Kobe C, et al. Involved-site radiotherapy is equally effective and less toxic than Involved-field radiotherapy in patients receiving combined modality treatment for early-stage unfavorable Hodgkin lymphoma - an analysis of the randomized phase III HD17 trial of the Germ. Int J Radiat Oncol Biol Phys. 2024.
2023
Fuchs M, Jacob ASophie, Kaul H, Kobe C, Kuhnert G, Pabst T, Greil R, Bröckelmann PJ, Topp MS, Just M, et al. Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma. Leukemia. 2023.
2022
Sasse S, Bröckelmann PJan, Momotow J, Plütschow A, Hüttmann A, Basara N, Koenecke C, Martin S, Bentz M, Grosse-Thie C, et al. AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trial. Leuk Lymphoma. 2022:1-8.
Gillessen S, Pluetschow A, Vucinic V, Ostermann H, Kobe C, Bröckelmann PJ, Böll B, Eichenauer DA, Heger J-M, Borchmann S, et al. JAK Inhibition with Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma: Final Results of A Phase II, Open Label, Multicenter Clinical Trial (JeRiCHO). Eur J Haematol. 2022.
Bröckelmann PJ, Bühnen I, Meissner J, Trautmann-Grill K, Herhaus P, Halbsguth TV, Schaub V, Kerkhoff A, Mathas S, Bormann M, et al. Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial. J Clin Oncol. 2022:JCO2202355.
Eichenauer DA, Bühnen I, Plütschow A, Kobe C, Dietlein M, Wendtner C-M, Thorspecken S, Topp MS, Mauser M, von Tresckow B, et al. Phase II study of fixed-duration single-agent ibrutinib in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. Hematol Oncol. 2022.
2021
Borchmann P, Plütschow A, Kobe C, Greil R, Meissner J, Topp MS, Ostermann H, Dierlamm J, Mohm J, Thiemer J, et al. PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(2):223-234.